# Liquid Biopsy Market

> Informe de Investigación del Mercado de Biopsia Líquida: Tamaño, Participación, Análisis de Tendencias por Aplicaciones (Diagnóstico de Cáncer, Monitoreo de Tratamiento, Monitoreo de Recurrencia, Ensayos Clínicos, Aplicaciones de Investigación), por Tipo de Muestra (Sangre, Orina, Saliva, Líquido Pleural, Líquido Cefalorraquídeo), por Tecnología (Secuenciación de Nueva Generación, PCR Digital, Microfluidos, Aislamiento de Exosomas, Células Tumorales Circulantes), por Uso Final (Hospitales, Laboratorios de Diagnóstico, Institutos de Investigación, Empresas Farmacéuticas) y por Regional (América del Norte, Europa, América del Sur, Asia-Pacífico, Medio Oriente y África) - Perspectivas de Crecimiento y Pronóstico de la Industria 2025 a 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.52%
- **2024:** $ 9.1 Billion
- **2025:** $ 10.06 Billion
- **2035:** $ 27.34 Billion
- **Key Players:** Companies such as Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Sysmex Corporation (JP), Roche Diagnostics (CH), Qiagen (DE), Thermo Fisher Scientific (US), Illumina (US) are some of the major participants in the global market.

**Report ID:** MRFR/HC/0239-CR · **Pages:** 171 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710

---

## Market Summary

As per Market Research Future Reports analysis, the Liquid Biopsy Market size was valued at USD 9.1 Billion in 2024. The market is projected to grow from USD 10.06 Billion in 2025 to USD 27.34 Billion by 2035, exhibiting a CAGR of 10.52% during the forecast period 2025–2035. North America led the market with over 49.45% share, generating around USD 4.5 Billion in revenue.
 
The Liquid Biopsy Market is primarily driven by increasing demand for non-invasive cancer diagnostics and rising adoption of precision medicine, enabling early detection, real-time monitoring, and personalized treatment approaches, thereby improving patient outcomes and accelerating adoption across oncology care globally.
 
According to the World Health Organization (WHO), cancer causes nearly 10 million deaths annually, making early detection critical for survival. This rising burden is accelerating demand for non-invasive diagnostic solutions like liquid biopsy, enabling timely diagnosis and improved treatment outcomes across global healthcare systems.

## Market Drivers

### Rising Incidence of Cancer

La creciente prevalencia del cáncer a nivel mundial sirve como un impulsor principal para la Industria del Mercado Global de Biopsias Líquidas. A medida que aumentan los casos de cáncer, la demanda de soluciones para la detección temprana y el monitoreo se intensifica. Las biopsias líquidas ofrecen una alternativa no invasiva a las biopsias de tejido tradicionales, permitiendo el análisis del ADN tumoral circulante. Por ejemplo, la Organización Mundial de la Salud indica que se espera que los casos de cáncer alcancen los 30 millones para 2040. Esta creciente población de pacientes probablemente impulsará el mercado, con proyecciones que estiman que el Mercado Global de Biopsias Líquidas alcanzará los 8.9 mil millones de USD en 2024 y potencialmente 22.9 mil millones de USD para 2035.

## Future Outlook

Se proyecta que el tamaño del mercado de biopsia líquida alcanzará los 27.34 mil millones de USD para 2035, creciendo a una tasa compuesta anual del 10.52%, impulsado por avances tecnológicos, el aumento de la prevalencia del cáncer y la demanda de diagnósticos no invasivos.

Para 2035, se espera que el mercado de biopsia líquida sea un componente fundamental de los diagnósticos de cáncer.

## Segment Insights

### Por Aplicación: Oncología (Más Grande) vs. Pruebas Prenatales (Crecimiento Más Rápido)

En el Mercado de Biopsia Líquida, la Oncología lidera como el segmento de aplicación predominante, contribuyendo significativamente a la dinámica general del mercado. Su fuerte participación de mercado del 66% refleja la creciente prevalencia del cáncer, junto con un aumento en el énfasis en la detección temprana y enfoques de tratamiento personalizados. Por el contrario, las Pruebas Prenatales están surgiendo como el segmento de más rápido crecimiento, impulsadas por los avances en tecnología que mejoran la precisión y la creciente demanda de opciones de pruebas prenatales no invasivas entre los padres expectantes. Las tendencias de crecimiento en el mercado son impulsadas principalmente por la creciente adopción de biopsias líquidas sobre biopsias de tejido tradicionales, debido a su naturaleza mínimamente invasiva y su capacidad para proporcionar información en tiempo real. Además, factores como los avances tecnológicos, el apoyo regulatorio y el aumento del gasto en salud están alimentando la expansión del mercado. Además, un aumento en la conciencia de los beneficios de la biopsia líquida está fomentando un entorno favorable para las pruebas prenatales y las aplicaciones de enfermedades infecciosas.

Oncología: Dominante vs. Pruebas Prenatales: Emergente

La Oncología, como el segmento de aplicación dominante en el mercado de biopsia líquida, se caracteriza por su extensa utilización en el diagnóstico y monitoreo del cáncer, ayudando en estrategias de tratamiento precisas. El segmento se beneficia de innovaciones tecnológicas robustas que mejoran la sensibilidad y especificidad de las metodologías de detección del cáncer. En contraste, las Pruebas Prenatales son un segmento emergente que está ganando tracción debido a su naturaleza no invasiva, lo que lo hace atractivo para los padres expectantes. Su crecimiento está respaldado por avances en tecnologías de NIPT (pruebas prenatales no invasivas), que mejoran la precisión en la detección de anomalías genéticas y brindan tranquilidad a los padres. Juntos, estos segmentos ilustran el paisaje en evolución de las biopsias líquidas, posicionándolas en la vanguardia de las aplicaciones de [medicina de precisión](https://www.marketresearchfuture.com/reports/precision-medicine-market-925).

### Por Tipo de Muestra: Sangre (Más Grande) vs. Orina (Crecimiento Más Rápido)

Entre los tipos de muestra analizados en el mercado de biopsia líquida, la sangre representa la mayor parte con un 69% debido a su amplia aceptación y utilidad en entornos clínicos para una variedad de cánceres. Sirve como el medio principal para detectar ADN tumoral circulante, convirtiéndola en una herramienta esencial para diagnósticos no invasivos. Después de la sangre, la orina está surgiendo rápidamente, impulsada por sus métodos de recolección mínimamente invasivos y la creciente adopción en sistemas de detección temprana de cáncer.

Sangre (Dominante) vs. Orina (Emergente)

El tipo de muestra de sangre sigue siendo dominante en el mercado de biopsia líquida, ya que facilita un análisis integral de la dinámica tumoral a través de células tumorales circulantes y ADN libre de células. Su papel establecido en oncología y su compatibilidad con varias tecnologías han consolidado su posición. Por otro lado, la orina es un tipo de muestra emergente, ganando tracción debido a innovaciones en técnicas de detección. Su facilidad de recolección la hace atractiva para la adherencia del paciente y las pruebas a gran escala, particularmente para el cáncer de vejiga y otras malignidades urológicas. A medida que avanza la investigación, se espera que las biopsias líquidas basadas en orina ocupen un nicho significativo junto a los métodos basados en sangre.

### Por Tecnología: Secuenciación de Nueva Generación (Más Grande) vs. PCR Digital (Crecimiento Más Rápido)

En el Mercado de Biopsia Líquida, la segmentación por tecnología revela que la Secuenciación de Nueva Generación (NGS) tiene la mayor participación de mercado con un 61%, impulsada por sus capacidades avanzadas en análisis genómico y cribado de alto rendimiento. La PCR digital sigue de cerca, emergiendo como un competidor significativo y atendiendo a la cuantificación precisa de ADN, lo que la hace vital para monitorear las respuestas al tratamiento de manera efectiva. Mientras tanto, otras tecnologías como Microfluídica, Espectrometría de Masas y Tecnología de Células Tumorales Circulantes también juegan roles esenciales pero representan porciones más pequeñas del mercado total.

Secuenciación de Nueva Generación (Dominante) vs. PCR Digital (Emergente)

La Secuenciación de Nueva Generación (NGS) lidera el Mercado de Biopsia Líquida debido a su capacidad para analizar vastas cantidades de información genómica rápidamente, permitiendo la detección temprana del cáncer y la medicina personalizada. Sus avances tecnológicos la han establecido como una opción preferida tanto para investigadores como para clínicos. En contraste, la PCR digital está ganando impulso como una tecnología emergente favorecida por su sensibilidad y especificidad en la cuantificación de mutaciones raras, lo cual es crucial en el monitoreo del tratamiento y la evaluación de la progresión. A medida que la atención médica enfatiza la medicina de precisión, se anticipa que la tracción de la PCR digital crecerá significativamente debido a su rendimiento superior en la detección de objetivos de baja abundancia.

### Por Usuario Final: Hospitales (Más Grande) vs. Laboratorios de Diagnóstico (Crecimiento Más Rápido)

En el Mercado de Biopsia Líquida, los hospitales tienen la mayor participación entre los usuarios finales con un 58%, impulsados por sus capacidades integrales en el cuidado del paciente y tecnologías de diagnóstico avanzadas. Sirven como centros centrales para realizar procedimientos de biopsia líquida, resultando en el mayor volumen de pruebas realizadas. En contraste, los laboratorios de diagnóstico están experimentando un crecimiento rápido, impulsados por la creciente demanda de diagnósticos de cáncer oportunos y precisos, lo que lleva a un aumento significativo en la oferta de servicios y avances tecnológicos en entornos de laboratorio.

Hospitales (Dominante) vs. Laboratorios de Diagnóstico (Emergente)

Los hospitales desempeñan un papel dominante en el Mercado de Biopsia Líquida debido a sus servicios de salud integrados y su capacidad para proporcionar atención inmediata al paciente, lo que mejora la adopción de pruebas de biopsia líquida. Su infraestructura establecida para diagnósticos complejos apoya un entorno próspero para soluciones innovadoras de detección de cáncer. Por otro lado, los laboratorios de diagnóstico están emergiendo como actores cruciales, beneficiándose de su enfoque especializado en pruebas y análisis. Este sector está evolucionando rápidamente para incorporar tecnologías avanzadas que satisfacen la creciente necesidad de servicios de diagnóstico precisos y eficientes. A medida que más laboratorios invierten en las capacidades para realizar biopsias líquidas, se posicionan como contribuyentes vitales a la expansión del mercado.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America leads in Liquid Biopsy Market Size, accounting for over 49.45% of the global revenue in 2024. The region's growth is driven by increasing cancer prevalence, advancements in technology, and supportive regulatory frameworks. The FDA's focus on expediting the approval of liquid biopsy tests has further catalyzed market expansion, making it a hub for innovation and research in oncology diagnostics.

The United States is the primary contributor to this market, with key players like Guardant Health, Exact Sciences, and GRAIL leading the charge. The competitive landscape is characterized by continuous innovation and strategic partnerships among companies. The presence of established firms and a robust healthcare infrastructure positions North America as a formidable force in the liquid biopsy sector.

Growth is driven by high cancer prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative diagnostic technologies. The Centers for Disease Control and Prevention (CDC) reports that cancer is the second leading cause of death in the U.S., with millions of new cases diagnosed annually. This significant burden is driving adoption of advanced diagnostics like liquid biopsy for early detection and personalized treatment.

### Europe : Emerging Market with Growth Potential

Europe Liquid Biopsy Market size was valued at USD 2.73 billion in 2024, making it the second-largest regional market with 30% share. The growth is fueled by increasing awareness of early cancer detection and the adoption of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937). Regulatory bodies are also playing a crucial role, with the European Medicines Agency (EMA) actively promoting the development of innovative diagnostic solutions, which is expected to enhance market dynamics significantly.

Leading countries in this region include Germany, the UK, and France, where significant investments in healthcare technology are being made. The competitive landscape features key players like Roche Diagnostics and Qiagen, who are focusing on expanding their product offerings. The collaboration between public and private sectors is fostering innovation, making Europe a promising market for liquid biopsy advancements.

Growth is driven by increasing awareness of early cancer detection, adoption of personalized medicine, and supportive regulatory frameworks. According to the World Health Organization (WHO), cancer remains a leading cause of mortality across Europe, accounting for millions of cases annually. Increasing healthcare investments and adoption of advanced diagnostic technologies are enhancing early detection capabilities and driving market growth.

### Asia-Pacific : Rapidly Growing Market Landscape

The Asia-Pacific region is witnessing a burgeoning liquid biopsy market, valued at 1.82 in 2024. This growth is driven by rising healthcare expenditures, increasing cancer incidences, and a growing emphasis on early diagnosis. Governments in countries like China and India are investing heavily in healthcare infrastructure, which is expected to further propel market growth and accessibility of liquid biopsy tests.

China and Japan are leading the charge in this region, with significant contributions from companies like Sysmex Corporation. The competitive landscape is evolving, with both local and international players vying for market share. The increasing collaboration between research institutions and biotech firms is fostering innovation, making Asia-Pacific a key player in The Liquid Biopsy.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region represents a nascent liquid biopsy market, with a size of 0.1 in 2024. The growth potential is significant, driven by increasing cancer awareness and the need for advanced diagnostic solutions. However, challenges such as limited healthcare infrastructure and regulatory hurdles may impede rapid market development.

Governments are beginning to recognize the importance of early cancer detection, which could catalyze future growth. Countries like South Africa and the UAE are at the forefront of adopting innovative healthcare solutions. The competitive landscape is still developing, with a few key players beginning to establish a presence. As investments in healthcare technology increase, the MEA region is poised for gradual growth in the liquid biopsy market, albeit at a slower pace compared to other regions.

## Competitive Benchmarking

The Liquid Biopsy Market is currently characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for non-invasive diagnostic solutions. Key players such as Guardant Health (US), Exact Sciences (US), and Roche Diagnostics (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Guardant Health (US) focuses on innovation in genomic profiling, aiming to provide comprehensive insights into cancer treatment.
 
Meanwhile, Exact Sciences (US) emphasizes partnerships with healthcare providers to expand its testing capabilities, thereby enhancing patient access to liquid biopsy solutions. Roche Diagnostics (CH) leverages its extensive research and development resources to integrate liquid biopsy technologies into its existing diagnostic portfolio, thereby reinforcing its competitive edge.The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market penetration. The Liquid Biopsy Market appears moderately fragmented, with a mix of established players and emerging startups. This structure allows for a diverse range of offerings, although the influence of major companies is substantial. Localizing manufacturing and optimizing supply chains are common strategies among these firms, aimed at reducing costs and improving service delivery.
 

In November Guardant Health (US) announced a strategic partnership with a leading healthcare provider to enhance its liquid biopsy testing services. This collaboration is expected to facilitate broader access to its innovative genomic tests, potentially increasing its market share and reinforcing its position as a leader in the field. The strategic importance of this partnership lies in its ability to streamline patient access to advanced diagnostics, thereby improving clinical outcomes.
 

In October Exact Sciences (US) launched a new liquid biopsy test designed to detect multiple cancer types at earlier stages. This introduction not only showcases the company's commitment to innovation but also positions it to capture a larger segment of the market focused on early detection. The significance of this launch is underscored by the growing emphasis on preventive healthcare, which is likely to drive demand for such diagnostic solutions.
In September Roche Diagnostics (CH) expanded its liquid biopsy product line by acquiring a startup specializing in next-generation sequencing technologies.
 
This acquisition is indicative of Roche's strategy to enhance its technological capabilities and diversify its offerings. The integration of advanced sequencing technologies is expected to bolster Roche's competitive position by providing more accurate and comprehensive diagnostic solutions.
As of December the market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing operational efficiencies. The shift from price-based competition to a focus on technological advancement and supply chain reliability is becoming increasingly evident. Moving forward, competitive differentiation is likely to hinge on the ability to innovate and deliver reliable, high-quality diagnostic solutions.

## Recent News & Developments

Recent developments in the Global Liquid Biopsy Market have seen significant advancements, with liquid biopsy companies like GRAIL and Exact Sciences pushing innovative technologies and applications. Major players are expanding their portfolios and improving diagnostic capabilities for early cancer detection.

In September 2023, Natera Incorporated announced the successful launch of a new assay aimed at enhancing non-invasive prenatal testing, showcasing a potential overlap in liquid biopsy technology. Meanwhile, in August 2023, a collaboration between Foundation Medicine and Roche focused on integrating liquid biopsies into their existing genomic profiling services, emphasizing the increased relevance of these tests in personalized medicine. This also aims to reduce the liquid biopsy cost.

On the mergers and acquisitions front, Thermo Fisher Scientific acquired Brammer Bio in December 2022, with implications for its liquid biopsy capabilities. Growth in market valuation continues to accelerate, attributed to rising collaborations across liquid biopsy companies, including Guardant Health and Illumina, as they enhance product offerings and expand their reach in the oncology segment.

Significant happenings over the last few years include the establishment of regulatory frameworks facilitating liquid biopsy integration into clinical practices, further confirming their positioning in oncology diagnostics on a global scale.

## Report Scope

| MARKET SIZE 2024 | 9.1(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 10.06(USD Billion) |
| MARKET SIZE 2035 | 27.34(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Sysmex Corporation (JP), Roche Diagnostics (CH), Qiagen (DE), Thermo Fisher Scientific (US), Illumina (US) |
| Segments Covered | Application, Technology, End Use |
| Key Market Opportunities | Advancements in non-invasive cancer diagnostics drive growth in the Liquid Biopsy Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the liquid biopsy market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Liquid Biopsy Market as of 2024?**
A: It was valued at 9.1 USD Billion in 2024.

**Q: What is the projected market size for the Liquid Biopsy Market by 2035?**
A: The market is projected to reach 27.34 USD Billion by 2035.

**Q: What is the expected CAGR for the Liquid Biopsy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for during 2025 - 2035 is 10.52%.

**Q: Which application segment is anticipated to dominate the Liquid Biopsy Market?**
A: The Oncology application segment is expected to grow from 4.5 USD Billion to 13.5 USD Billion by 2035.

**Q: How does the market for Non-Oncology applications compare to Prenatal Testing?**
A: The Non-Oncology segment is projected to expand from 2.0 USD Billion to 6.0 USD Billion, while Prenatal Testing is expected to grow from 1.0 USD Billion to 3.0 USD Billion.

**Q: What are the leading sample types utilized in the Liquid Biopsy Market?**
A: Blood is anticipated to be the leading sample type, growing from 3.5 USD Billion to 10.5 USD Billion by 2035.

**Q: Which technology segment is likely to see the most growth in the Liquid Biopsy Market?**
A: Next Generation Sequencing is projected to increase from 2.73 USD Billion to 8.12 USD Billion during the forecast period.

**Q: What role do hospitals play in the Liquid Biopsy Market?**
A: Hospitals are expected to grow from 2.73 USD Billion to 8.12 USD Billion, indicating their significant role as end users.

**Q: Who are the key players in the Liquid Biopsy Market?**
A: Key players include Guardant Health, Exact Sciences, GRAIL, Freenome, and Roche Diagnostics.

**Q: What is the anticipated growth for the Diagnostic Laboratories segment?**
A: The Diagnostic Laboratories segment is expected to grow from 2.27 USD Billion to 6.81 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710*